Yuanying Fang

Dr. Yuanying Fang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YFYuanying Fang
Yuanying Fang
LHLamees Hegazy
Lamees Hegazy
Brian FinckBrian Finck
Brian Finck
Bahaa ElgendyBahaa Elgendy
Bahaa Elgendy

18 April 2024 in Bioorganic Chemistry
Verified
Journal Article
Closed access
ZCZhifang Cai
Zhifang Cai
ZYZunhua Yang
Zunhua Yang
HLHuilan Li
Huilan Li
YFYuanying Fang
Yuanying Fang

11 March 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
RWRyan D. Welch
Ryan D. Welch
CBCyrielle Billon
Cyrielle Billon
MLMcKenna Losby
McKenna Losby
GBGonzalo Bedia-Diaz
Gonzalo Bedia-Diaz
YFYuanying Fang
Yuanying Fang
KGKristine Griffett
Kristine Griffett
Non-alcoholic fatty liver (NAFLD) over the past years has become a metabolic pandemic linked to a collection of metabolic diseases. The nuclear receptors ERRs, REV-ERBs, RORs, FXR, PPARs, and LXR are master regulators of metabolism and liver physiology. The characterization of these nuclear receptors and their biology has promoted the development of synthetic ligands. The possibility of targeting these receptors to treat NAFLD is promising, as several compounds including Cilofexor, thiazolidinediones, and Saroglitazar are currently undergoing clinical trials. This review focuses on the latest development of the pharmacology of these metabolic nuclear receptors and how they may be utilized to treat NAFLD and subsequent comorbidities.

24 July 2021 in Molecules
Verified
Journal Article
Open access
PDF file
MCMeng Cheng
Meng Cheng
QLQiaoming Liu
Qiaoming Liu
TGTiantian Gan
Tiantian Gan
YFYuanying Fang
Yuanying Fang
YPYue Pengfei
Yue Pengfei
LTLiangxing Tu
Liangxing Tu
Prolonging in vivo circulation has proved to be an efficient route for enhancing the therapeutic effect of rapidly metabolized drugs. In this study, we aimed to construct a nanocrystal-loaded micelles delivery system to enhance the blood circulation of docetaxel (DOC). We employed high-pressure homogenization to prepare docetaxel nanocrystals (DOC(Nc)), and then produced docetaxel nanocrystal-loaded micelles (DOC(Nc)@mPEG-PLA) by a thin-film hydration method. The particle sizes of optimized DOC(Nc), docetaxel micelles (DOC@mPEG-PLA), and DOC(Nc)@mPEG-PLA were 168.4, 36.3, and 72.5 nm, respectively. The crystallinity of docetaxel was decreased after transforming it into nanocrystals, and the crystalline state of docetaxel in micelles was amorphous. The constructed DOC(Nc)@mPEG-PLA showed good stability as its particle size showed no significant change in 7 days. Despite their rapid dissolution, docetaxel nanocrystals exhibited higher bioavailability. The micelles prolonged the retention time of docetaxel in the circulation system of rats, and DOC(Nc)@mPEG-PLA exhibited the highest retention time and bioavailability. These results reveal that constructing nanocrystal-loaded micelles may be a promising way to enhance the in vivo circulation and bioavailability of rapidly metabolized drugs such as docetaxel.

1 May 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZYZunhua Yang
Zunhua Yang
YYYuqi Ying
Yuqi Ying
SCShaobing Cheng
Shaobing Cheng
JWJiamin Wu
Jiamin Wu
ZZZiwei Zhang
Ziwei Zhang
YFYuanying Fang
Yuanying Fang

3 October 2023 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
FHFeng He
Feng He
YCYu Chai
Yu Chai
ZZZizhen Zeng
Zizhen Zeng
FLFangling Lu
Fangling Lu
HCHuanwen Chen
Huanwen Chen
YWYang Wan
Yang Wan